XML 44 R28.htm IDEA: XBRL DOCUMENT v3.26.1
Segments (Tables)
 6 Months Ended
Jun. 30, 2026
Segments  
Schedule of segment net loss (income) by significant expense category

The following table presents reportable segment net loss, including significant expense categories, attributable to the Company’s reportable segment for the three and six months ended June 30, 2026 and 2025 (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Six Months Ended

​

​

​

June 30, 

​

June 30, 

​

​

  ​ ​ ​

2026

  ​ ​ ​

2025

​

2026

  ​ ​ ​

2025

  ​ ​ ​

Compensation and benefits, excluding stock-based compensation

​

$

3,147

 

$

2,144

​

$

6,174

​

$

4,383

​

Stock-based compensation

​

​

2,609

 

​

1,256

​

​

5,259

 

​

2,507

​

Drug manufacturing

​

​

2,441

 

​

1,850

​

​

2,872

 

​

3,680

​

Clinical trials

​

​

5,410

 

​

2,135

​

​

10,453

 

​

4,062

​

Outside general and administrative

​

​

906

 

​

848

​

​

2,150

 

​

1,794

​

Facilities and insurance

​

​

630

 

​

504

​

​

1,188

 

​

1,284

​

Other segment items (1)

​

​

4,154

 

​

1,523

​

​

6,078

 

​

2,472

​

Total segment expense

​

​

19,297

 

​

10,260

​

​

34,174

 

​

20,182

​

Non-operating income, net

​

​

(1,338)

 

​

(2,262)

​

​

(2,523)

 

​

(27,377)

​

Net loss

​

$

17,959

 

$

7,998

​

$

31,651

 

$

(7,195)

​

(1)Includes consulting, non-clinical research and laboratory supplies.